Frequent dose interruptions are required for patients receiving oral kinase inhibitor therapy for advanced renal cell carcinoma. [electronic resource]
Producer: 20100628Description: 217-20 p. digitalISSN:- 1537-453X
- Administration, Oral
- Adult
- Aged
- Angiogenesis Inhibitors -- administration & dosage
- Antineoplastic Agents -- administration & dosage
- Benzenesulfonates -- administration & dosage
- Carcinoma, Renal Cell -- drug therapy
- Disease Progression
- Drug Administration Schedule
- Drug Eruptions -- etiology
- Female
- Humans
- Hypertension -- chemically induced
- Hypothyroidism -- chemically induced
- Indoles -- administration & dosage
- Kidney Neoplasms -- drug therapy
- Male
- Middle Aged
- Niacinamide -- analogs & derivatives
- Phenylurea Compounds
- Protein Kinase Inhibitors -- administration & dosage
- Pyridines -- administration & dosage
- Pyrroles -- administration & dosage
- Retrospective Studies
- Sorafenib
- Sunitinib
No physical items for this record
Publication Type: Journal Article
There are no comments on this title.
Log in to your account to post a comment.